CLINICAL TRIALS DISCoVeRy
A multicenter, adaptive, randomized study of the safety and efficacy of treatment in hospitalized adult patients with COVID-19.
The treatment of COVID-19 is still a major challenge for medical research, so new drugs are being investigated or the use of existing drugs is being optimized. One of the new medicines is a cocktail of two monoclonal antibodies developed by AstraZeneca. The DisCoVeRy clinical trial aims to evaluate the efficacy and safety of different therapeutics compared to a control group. A total of 1260 patients are planned to be enrolled in the study. The sponsor of the multicentre clinical trial is the French National Institute for Health and Medical Research, which is implementing the study in three centres in the Czech Republic through VI CZECRIN.
OVERVIEW OF RECRUITMENT
Based on the decision of the Discovery Steering Committee, recruitment into the study was completed as of July 1, 2022, with a total of 237 patients enrolled. No patients were enrolled in the Czech Republic and the clinical trial was not initiated.
Important project links and documents
| EU Clinical Trials Register | KH registration on Clinicaltrials.gov |
| Official project website | Approval of KH MEK FN Brno |
Contact
Study sponsor:
INSERM | eu-response@inserm.fr
Project Manager:
Ing. Karolína Grodová | karolina.grodova@med.muni.cz